The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
A New Scrambled Antigen Vaccine (SAVINE) Approach: Proof-of-concept In Non-human Primates For HIV-1
Funder
National Health and Medical Research Council
Funding Amount
$120,700.00
Summary
The specific aim of this proposal is to demonstrate, in non-human primates, proof–of-concept of a patented new platform vaccine technology (scrambled antigen vaccine or SAVINE) designed to encode all the protein sequences of an infectious agent, in this case HIV-1. These are arranged as equal-sized, overlapping fragments such that all potential T cell epitopes that are needed to induce broad T-cell-mediated immunity are maintained. The synthetically designed vaccine uses consensus sequences of H ....The specific aim of this proposal is to demonstrate, in non-human primates, proof–of-concept of a patented new platform vaccine technology (scrambled antigen vaccine or SAVINE) designed to encode all the protein sequences of an infectious agent, in this case HIV-1. These are arranged as equal-sized, overlapping fragments such that all potential T cell epitopes that are needed to induce broad T-cell-mediated immunity are maintained. The synthetically designed vaccine uses consensus sequences of HIV-1 to provide universal coverage of the major HIV-1 strains for a global population. The synthetic systematically designed HIV-1 vaccine will be delivered using our newly developed prime-boost immunisation regime that induces particularly high levels of cell-mediated immunity.Read moreRead less
Long-lived CD8 T Cell Responses Induced By A Recombinant Cytomegalovirus Vector
Funder
National Health and Medical Research Council
Funding Amount
$234,750.00
Summary
The priming of the immune system to protect against infection and disease is an important means to alleviate these conditions. Current vaccination technologies often rely on multiple inoculations (prime-boosting). In addition, specific priming of the immune system against pathogens that target mucosal sites has been difficult and often lacks efficacy resulting in temporary or variable protection. Using a well developed mouse model for a common human virus, we have explored the potential of this ....The priming of the immune system to protect against infection and disease is an important means to alleviate these conditions. Current vaccination technologies often rely on multiple inoculations (prime-boosting). In addition, specific priming of the immune system against pathogens that target mucosal sites has been difficult and often lacks efficacy resulting in temporary or variable protection. Using a well developed mouse model for a common human virus, we have explored the potential of this agent as a vaccine agent, making use of its long term persistence in the infected host to provide continued antigenic stimulation of the immune system. We have found that very strong and long lasting responses can be elicited after a single inoculation of avirulent virus. In this study, this effect will be further explored and developed.Read moreRead less
Hypoallergenic Proteins As Novel Immunotherapeutic Candidates For Food Allergy
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
The rate of food allergy has tripled over the past decade and is a leading cause of food related anaphylaxis in Australia. Allergen immunotherapy can help patients develop tolerance to the allergenic food. This research will investigate the potential of hypoallergenic derivatives of two major food allergens as novel desensitisation therapeutics, addressing an issue of significant importance to human health, paving the way for research on advanced therapeutics for paediatric food allergy.
Characterisation Of A Novel Direct Electrochemical Chip As A Biosensor And Tool For Studying Redox-sensitive Proteins
Funder
National Health and Medical Research Council
Funding Amount
$144,500.00
Summary
Biosensors use biomolecules to detect a chemical event. They are becoming important for the rapid and reliable measurement of the concentrations of molecules in fluids. In human medicine they will be of great use to general practitioners and patients for instantaneous read outs of concentrations of many different biological molecules. How well a biosensor responds depends on the method in which the biomolecule is immobilised to a surface and the signal detected. We have made a significant advanc ....Biosensors use biomolecules to detect a chemical event. They are becoming important for the rapid and reliable measurement of the concentrations of molecules in fluids. In human medicine they will be of great use to general practitioners and patients for instantaneous read outs of concentrations of many different biological molecules. How well a biosensor responds depends on the method in which the biomolecule is immobilised to a surface and the signal detected. We have made a significant advance in biosensing capabilities using a recombinant protein (thioredoxin) and demonstrated the improvement that is possible by (i) immobilising the protein in a highly oriented way and (ii) using a sensitive electrical signal to monitor the response. Here we will undertake more comprehensive testing by extending the number of proteins to include the 4 major classes of redox-sensitive biomolecules (proteins) in the body. This will enable us to establish the broad application of our methods and substantially improve our ability to commercialize our discoveries.Read moreRead less